Brief: JPMorgan's Long Position In Ordinary Shares Of Clover Biopharmaceuticals Rises To 5.30% - Filing
23/12/2022 09:11
Dec 23 (Reuters) - Hong Kong stock exchange filing:
* JPMORGAN CHASE & CO'S LONG POSITION IN ORDINARY SHARES OF
CLOVER
BIOPHARMACEUTICALS 2197.HK INCREASED TO 5.30% ON DEC 19 FROM
4.49% - HKEX FILING
Source text
Further company coverage: 2197.HK
(Reporting by Hong Kong newsroom)
((twinnie.siu@tr.com; 852-3462 7715;))
Recent news on Clover Biopharmaceuticals
See all newsChina's Clover Biopharma H1 revenue drops sharply, flags going-concern doubt
Brief: Clover Biopharmaceuticals Posts FY Loss Of RMB205.1 MLN
Brief: Clover Announces Positive Phase I Clinical Data For Rsv-Hmpv-Piv3 Combination Vaccines And For Rsv Re-Vaccination In Older Adults
Brief: Clover Biopharmaceuticals Posts H1 Revenue Of RMB3.3 Million
Brief: Clover Biopharmaceuticals Says It Terminates Cooperation With Adimmune